What happened
The European regulatory review concluded that medicines containing Levamisole should no longer remain authorized in the EU because the risk-benefit balance became unfavorable.
The review was conducted by the European Medicines Agency and its Pharmacovigilance Risk Assessment Committee.
Main safety concern
The key concern was indeed leukoencephalopathy, especially inflammatory or multifocal forms affecting the brain’s white matter.
Reported effects included:
- Confusion
- Cognitive impairment
- Difficulty walking
- Weakness
- Seizures
- Other neurological symptoms
The concern became serious because:
- Cases could be severe or disabling
- Onset timing was unpredictable
- Some cases occurred after relatively limited exposure
Why regulators considered the benefit too low
Levamisole was primarily used as an antiparasitic medicine for worm infections. In modern European practice:
- These infections are usually manageable
- Safer alternatives are widely available
- The conditions treated were generally not life-threatening
Because effective substitutes exist, regulators determined that even a rare risk of serious neurological injury was unacceptable.
Additional context
Levamisole also has a complicated medical history:
- It was previously used as an immune-modulating drug in some cancers and autoimmune diseases
- Many countries had already restricted or discontinued its use years earlier because of adverse effects such as:
- Agranulocytosis (dangerously low white blood cells)
- Vasculitis
- Neurological toxicity
It is also known outside medicine because it has sometimes been found as an adulterant in illicit cocaine, where it has caused additional toxic effects.
Important nuance
The withdrawal does not necessarily mean:
- Everyone who took levamisole is in danger
- Neurological injury is common
The adverse event is considered rare, but regulators judged the severity too high relative to the limited therapeutic benefit.
Good advice for patients
Your patient guidance is appropriate:
- Speak with a doctor or pharmacist
- Do not abruptly stop prescribed treatment without medical advice
- Ask about alternatives if treatment is still needed
People who previously took levamisole and have no neurological symptoms generally do not need to panic, but should seek medical attention if unusual neurological symptoms appear.
Core regulatory principle
Your concluding point is exactly right:
Medicines remain approved only while their benefits outweigh their risks.
In this case:
- Benefit: treatment of relatively mild, treatable conditions
- Risk: rare but potentially severe neurological complications
That balance led European regulators to support market withdrawal.
